The effect of Ezetimibe in hypercholesterolemic patients with Nonaicoholic fatty liver disease(NAFLD)

The effect of Ezetimibe in hypercholesterolemic patients with Nonaicoholic fatty liver disease(NAFLD) - The effect of Ezetimibe in patients with Nonaicoholic fatty liver disease(NAFLD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002440

Enrollment

Registered

2009-10-01

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonaicoholic fatty liver disease

Interventions

Ezetimibe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hypercholesterolemic patients with NAFLD meeting following status: 1.diagnosed NAFLD by liver biopsy 2.continuing current treatment over 3months 3.over 20years old

Exclusion criteria

Exclusion criteria: 1.patients being taken Ezetimibe 2.patients with serious liver disease 3.secondary hyperlipidemia or drug-induced hyperlipidemia 4.pregnant or lactating women 5.aicoholconsumption>21g/day

Design outcomes

Primary

Measure	Time frame
1) Histological and immunohistochemical analysis of analysis of liver 2) L/S ratio by CT 3) Various biological markers of liver didease.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026